Pre-vaccine serotype composition within a lineage signposts its serotype replacement – a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK

Rebecca A. Gladstone(Wellcome Sanger Institute), Stuart C. Clarke(University Hospital Southampton NHS Foundation Trust), Saul N. Faust(University Hospital Southampton NHS Foundation Trust), Stephen D. Bentley(Wellcome Sanger Institute), Vanessa T. Devine(University of Southampton), David Cleary(University of Birmingham), Jessica Jones(University of Southampton), Johanna M. Jefferies(University Hospital Southampton NHS Foundation Trust)
Microbial Genomics
June 8, 2017
10.1099/mgen.0.000119
Cited by 32

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
|The Lancet|2020|5k
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18
|Nature|2001|1.3k
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
|The Lancet|2021|1.2k
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
|Pediatric Critical Care Medicine|2020|1.2k